Biopharma CMO company Samsung Biologics disclosed on Monday the launch of a long-term agreement with Ichnos Sciences for manufacturing drug substance for ISB 830 as a potential treatment for moderate-to-severe atopic dermatitis.
The companies added that ISB 830, which is an anti-OX40 monoclonal antibody in development, has the potential to treat a range of autoimmune diseases beyond atopic dermatitis based on an entirely new mechanism of action. The prevalence of atopic dermatitis in the seven major markets (US, France, Germany, Italy, Spain, the UK, and Japan) currently exceeds 80 million patients.
Recently, the partnership has concluded the enrollment under a large randomised placebo-controlled Phase 2b study in atopic dermatiti and the results are expected in the first half of 2020.
Under a prior Master Services Agreement, Samsung Biologics has provided Ichnos with process optimization and manufacturing services.
As part of the Master Services Agreement with Ichnos, Samsung Biologic will continue to manufacture drug substance for ISB 830 Phase 3 clinical trials and for potential future global commercial supply upon regulatory approval.
GlaxoSmithKline's Nucala succeeds in phase three hypereosinophilic syndrome study
Calliditas Therapeutics appoints new CMO
Promethera Biosciences, Medipal Enter Alliance Pact
Merck's ERVEBO Ebola Zaire Vaccine Granted Conditional Approval in the European Union
NEC and Vaximm Forge Clinical Trial Collaboration
US FDA grants Breakthrough Therapy Designation to X4 Pharmaceuticals' mavorixafor